Pay in 4 interest-free payments of $6.86 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
doi: 10.3389/fnut.2026.1833045 Received 17 March 2026 Revised 04 April 2026 Accepted 09 April 2026 Published 27 April 2026 Volume 13 - 2026 Edited by Michele Barone, University of Bari Aldo Moro, Italy Reviewed by Alejandro Bruna, Universidad de Playa Ancha, Chile Umesh Singh, Shyam Shah Medical College, India Updates Copyright 2026 Israel, Moed, Abo Fanne, Kedem, Odeh, Rashed, Marzook, Abumouch and Fanne
Clinical trials have shown that semaglutide can decrease the risk of major cardiovascular events or death by 26% in people with diabetes
On multivariate analysis, compared to patients without EHR, patients with EHR (without IHR) showed higher portion of venous/lymphatic involvement (HR 2.418, p=0.020), tumor necrosis (HR 2.592, p=0.009) and initial tumor stage beyond Milan criteria (HR=3.008, p=0.001)
insulin resistance dampens the signal
6 Burns, A.M., Solch, R.J., Dennis-Wall, J.C., Ukhanova, M., Nieves Jr., C., Mai, V., Christman, M.C., Gordon, D.T., Langkamp-Henken, B
US$ 21.61
US$ 21.10
US$ 21.70
US$ 21.37
US$ 25.97
US$ 27.53
US$ 29.87
